Mandate

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm

February 27, 2014

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm and Nordic Capital Fund V:s offering of shares in connection with the listing. Bufab is a trading company that delivers components and services to the global manufacturing industry. Bufab is a trading company that delivers components and services to the global manufacturing industry. The Company offers its customers a one-stop-shop product offering that covers sourcing, quality assurance and logistics of so called C-Parts, components such as nuts, screws and washers, according to the business model Supply Chain Partner. The Swedish language prospectus was published on 10 February 2014 and the first day of trading was 21 February 2014. The offering attracted strong interest among Swedish and international institutional investors as well as Swedish retail investors. The Offering was over-subscribed multiple times. The final offering price has been set at SEK 46 per share, corresponding to a market value of all shares issued by Bufab of MSEK 1,753.

Vinge’s team consisted of, among others, partners Charlotte Levin, Peter Bäärnhielm and Christina Kokko and associates Jonas Johansson, David Andersson, Mia Örnfeldt, Albert Wållgren and Rikard Lindahl.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025